Related references
Note: Only part of the references are listed.CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases
Jianda Yuan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Prognostic value of tumor-infiltrating Foxp3+T-cell subpopulations in metastatic melanoma
Anne C. Knol et al.
EXPERIMENTAL DERMATOLOGY (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Gene Signature in Melanoma Associated With Clinical Activity A Potential Clue to Unlock Cancer Immunotherapy
Thomas F. Gajewski et al.
CANCER JOURNAL (2010)
Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
Michal J. Besser et al.
CLINICAL CANCER RESEARCH (2010)
Comparison of three culture media for the establishment of melanoma cell lines
M. C. Pandolfino et al.
CYTOTECHNOLOGY (2010)
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
Helena Harlin et al.
CANCER RESEARCH (2009)
Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
Antoni Ribas et al.
CLINICAL CANCER RESEARCH (2009)
Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma
Amir Khammari et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
ME Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immunoregulatory T cells in tumor immunity
M Terabe et al.
CURRENT OPINION IN IMMUNOLOGY (2004)
In vitro induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 expression in keratinocytes by boron and manganese
N Chebassier et al.
EXPERIMENTAL DERMATOLOGY (2004)
Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients
N Labarrière et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma
B Dréno et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus:: predictability and relation with disease advancement
MC Pandolfino et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2001)